WHO Raises Concern Over Critical Lack of Obesity Jabs
Under a tenth of people who could benefit from GLP-1 drugs such as Wegovy can access them, states the World Health Organization as it issues its initial guidance on the therapies.
Considering in excess of 1,000,000,000 people worldwide currently obese, it is calling for increased and just access to GLP-1 medication.
According to estimates, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"The latest guidance recognises that obesity is a long-term condition that can be treated with comprehensive and continuous support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and logistical bottlenecks are major hurdles to universal access to the jabs that can assist patients in reducing significant weight, explains the agency.
Skinny Jab Scarcity
Despite the present best projected case, the production of these medications might only reach around 100 million people – under 10% of eligible patients, per the health organization.
The guideline calls on nations and manufacturers to increase access, via strategies such as voluntary licensing.
A patent on a key compound – the core ingredient of a leading brand – is scheduled to end in multiple countries in 2026.
The Way Weight-Loss Injections Work
The injections mimick a natural hormone to reduce digestion speed, reduce hunger and boost satiety so people consume fewer calories.
Patients commonly start to lose weight within a few weeks of starting on the regular doses.
Research suggests users may put most of the weight back on a year later of discontinuing the medication, as their typical hunger return.
To be above a healthy weight elevates your likelihood for contracting health problems, including diabetes, cardiovascular issues, brain attack, and some malignancies.
Obesity affects individuals in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, as per the WHO.
